Product Description
ION455, also known as AZD7503, is an investigational antisense medicine designed for the treatment of nonalcoholic steatohepatitis (NASH). (Sourced from: https://www.ionispharma.com/ionis-innovation/pipeline/)
Mechanisms of Action: HSD17B13 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Fatty Liver, Alcoholic|Healthy Volunteers|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2071230075 | P1 |
Recruiting |
Fatty Liver, Alcoholic |
2024-12-31 |
|
| D9230C00003 | P1 |
Completed |
Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Diseases, Alcoholic |
2024-02-27 |
21% |
| D9230C00001 | P1 |
Completed |
Healthy Volunteers |
2022-11-09 |
28% |